Medicenna Therapeutics Corp. (TSX:MDNA)

Medicenna Therapeutics Corp offers therapeutics treatment for cancer and other autoimmune and neuroinflammatory diseases.

It is an immuno-oncology clinical-stage company that focuses on the development of IL-2, IL-4 and IL-13 Superkines.

Superkines boosts the immune system and helps patients to fight diseases, the medical company claims.

The company aims to develop life-changing therapies for people across the globe using three major families of interleukins, namely IL-2, IL-4 and IL-13. It further claims that these interleukins provide immune activity to over 2000 different diseases. The interleukins are transformed to SuperKines to boost the immune system and help fight cancer, autoimmune and neuroinflammatory diseases.

The clinical-stage company says that interleukins are a group of cytokines or cellular messenger molecules that make the immune system stable. In addition, it emphasizes that its Superkine Platform could alter tumor microenvironment and deliver cell-killing agents or inhibit the destructive autoimmune processes.

The company says three interleukins usually function well but seldom need a push to treat the diseases without causing any toxicity.

Furthermore, the immune-oncology firm aims to fuse Superkines with cytokines, proteins, antibodies, and even toxins to increase functionality and transform to empowered Superkines.

Medicennas’ product pipeline consists of pre-clinical candidates, namely:

• MDNA55
• MDNA11
• MDNA209
• MDNA413
• MDNA132

The company has developed an empowered Superkine MDNA55 used to treat a fatal form of brain cancer. It uses specific IL-4 Superkine to reactivate the immune system and fight glioblastoma multiforme (rGBM). The medical company claims that the product pipeline has completed the Phase 2b clinical trial for rGBM.

MDNA11

The second candidate, MDNA11, is developed to fight solid tumors by using long-acting IL-2 Superkine fused with recombinant albumin to minimize dosing requirement and increase immune cells. In addition, it activates the cancer-killing immune cells such as naive T cells, natural killer cells and cytotoxic T cells.

BiSKITs

BiSKITs or Bi-functional SuperKine ImmunoTherapies function as a single molecule and can target cancers in cases when other immunotherapies were not satisfactory such as cold tumors, the medical firm claims. Cold tumors are types of cancer, including pancreatic, prostate and glioblastoma.

In addition, the firm says that BiSKITs with solo Superkine can break the defense of these cold tumors.